GLP-1 Weight Loss Drugs (Wegovy, Zepbound) Insurance Denial Appeal — Free AI Letter
GLP-1 receptor agonists prescribed for chronic weight management - notably Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) - are among the most frequently denied prescription drug categories in 2024-2026. Insurers cite cost concerns, BMI thresholds, prior authorization criteria, exclusion of 'weight loss drugs' from the plan formulary, and required documentation of failed lifestyle interventions. The clinical evidence supporting these medications is extensive: they are FDA-approved for chronic weight management in patients with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related comorbidity. They reduce cardiovascular risk in patients with established cardiovascular disease (Wegovy received an FDA label expansion in 2024 for cardiovascular risk reduction in adults with cardiovascular disease and obesity or overweight). They are associated with sustained weight loss of 15-20% of body weight in clinical trials. Successful appeals lean heavily on medical necessity, the FDA-approved indication, comorbidity documentation, and where applicable, the cardiovascular risk reduction indication that elevates these drugs from 'lifestyle' to disease-modifying therapy.
Why insurers deny GLP-1 Weight Loss claims
The laws that help you appeal
There is no single federal statute that mandates coverage of obesity medications, but several layers of federal and state law support appeals. The Affordable Care Act, 42 USC 18022, includes prescription drugs as one of the ten essential health benefits for ACA-regulated plans, and state benchmark plans determine which drugs must be covered. ERISA, 29 USC 1132, provides the procedural framework for appeals of denied benefits in employer-sponsored plans, including the right to a full and fair review. State insurance codes typically require that medical-necessity determinations be made in accordance with generally accepted standards of medical practice, which for obesity now includes pharmacotherapy as recommended by the American Association of Clinical Endocrinology, Endocrine Society, and Obesity Medicine Association clinical practice guidelines. The FDA's approval of Wegovy for cardiovascular risk reduction in March 2024 is a significant lever: when a drug is approved to reduce cardiovascular events, denying it as a 'lifestyle' or 'cosmetic' drug becomes much harder to defend. For Medicare beneficiaries, the Treat and Reduce Obesity Act has been introduced multiple times but not enacted as of mid-2026, so traditional Medicare Part D plans generally still exclude weight-loss drugs - but the cardiovascular risk reduction indication may unlock coverage when the patient has documented cardiovascular disease.
Evidence to include in your appeal
- Letter of medical necessity from your prescribing physician documenting current BMI, weight history, comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, NAFLD, cardiovascular disease, PCOS), prior weight management interventions tried, and clinical rationale for the specific GLP-1 prescribed
- Records of prior lifestyle intervention attempts: dietary counseling, exercise programs, behavioral therapy, and other weight-loss medications tried, with documented results
- Citation to the FDA-approved indication for the drug requested (Wegovy, Zepbound, Saxenda label) including the cardiovascular risk reduction indication for Wegovy where applicable
- Citation to the relevant clinical practice guideline (AACE 2022 Obesity Algorithm, Endocrine Society clinical practice guideline, Obesity Medicine Association)
- If denied as off-label use of a diabetes drug, switch to the weight-management labeled formulation - prescribe Wegovy instead of Ozempic for weight loss
- Documentation of comorbidity severity and risk: HbA1c, blood pressure, lipid panel, cardiovascular workup, sleep study results
- Photograph of denial letter and all plan documents (formulary, drug benefit summary, prior authorization criteria) so the appeal can directly contest the specific criteria the plan applied
Winning strategy
Lead with the FDA-approved indication. If the plan claims the drug is 'not medically necessary' for weight management, that contradicts an explicit FDA approval - a powerful refutation. For Wegovy specifically, lean into the cardiovascular risk reduction indication when the patient has cardiovascular disease, because it reframes the drug from 'weight loss' to 'cardiovascular disease management' and undercuts the plan's category exclusion. If a step therapy denial is in play, document clinical reasons why the cheaper alternative is contraindicated, ineffective, or has caused intolerable side effects in this patient - a generic 'I want the newer drug' will not survive review. For BMI threshold disputes, cite the FDA label and the clinical practice guidelines that align with the FDA threshold. Always request that the appeal reviewer be a specialist in obesity medicine or endocrinology rather than a generalist. For ERISA plans, exhaust internal appeals to preserve the right to sue under 29 USC 1132(a)(1)(B). For ACA-regulated plans, escalate to external review through your state's process if internal appeals fail.
Relevant treatments and medications
Generate your GLP-1 Weight Loss appeal letter
Upload your denial notice or EOB. Our 5-agent AI pipeline drafts a professional appeal in about 2 minutes, free.
Upload my denial · Free